SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E, Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R, Mennen, M., Skelm, S., Wibmer, C. K., Bhiman, J. N, Ueckermann, V., Rossouw, T., Boswell, M., de Oliveira, T., Williamson, C., Burgers, W. A, Ntusi, N., Morris, L., & Moore, P. L bioRxiv, Cold Spring Harbor Laboratory, mar, 2021. ![SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.
@article{Moyo-Gwete2021a,
abstract = {Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90{\%} of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.},
author = {Moyo-Gwete, Thandeka and Madzivhandila, Mashudu and Makhado, Zanele and Ayres, Frances and Mhlanga, Donald and Oosthuysen, Brent and Lambson, Bronwen E and Kgagudi, Prudence and Tegally, Houriiyah and Iranzadeh, Arash and Doolabh, Deelan and Tyers, Lynn and Chinhoyi, Lionel R and Mennen, Mathilda and Skelm, Sango and Wibmer, Constantinos Kurt and Bhiman, Jinal N and Ueckermann, Veronica and Rossouw, Theresa and Boswell, Michael and de Oliveira, Tulio and Williamson, Carolyn and Burgers, Wendy A and Ntusi, Ntobeko and Morris, Lynn and Moore, Penny L},
doi = {10.1101/2021.03.06.434193},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Moyo-Gwete et al. - 2021 - SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.pdf:pdf},
journal = {bioRxiv},
keywords = {OA,fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,original},
month = {mar},
pages = {2021.03.06.434193},
pmid = {33688657},
publisher = {Cold Spring Harbor Laboratory},
title = {{SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/33688657 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941631},
year = {2021}
}
Downloads: 0
{"_id":"baGS5Fj6GCA65oQRW","bibbaseid":"moyogwete-madzivhandila-makhado-ayres-mhlanga-oosthuysen-lambson-kgagudi-etal-sarscov2501yv2b1351elicitscrossreactiveneutralizingantibodies-2021","author_short":["Moyo-Gwete, T.","Madzivhandila, M.","Makhado, Z.","Ayres, F.","Mhlanga, D.","Oosthuysen, B.","Lambson, B. E","Kgagudi, P.","Tegally, H.","Iranzadeh, A.","Doolabh, D.","Tyers, L.","Chinhoyi, L. R","Mennen, M.","Skelm, S.","Wibmer, C. K.","Bhiman, J. N","Ueckermann, V.","Rossouw, T.","Boswell, M.","de Oliveira, T.","Williamson, C.","Burgers, W. A","Ntusi, N.","Morris, L.","Moore, P. L"],"bibdata":{"bibtype":"article","type":"article","abstract":"Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.","author":[{"propositions":[],"lastnames":["Moyo-Gwete"],"firstnames":["Thandeka"],"suffixes":[]},{"propositions":[],"lastnames":["Madzivhandila"],"firstnames":["Mashudu"],"suffixes":[]},{"propositions":[],"lastnames":["Makhado"],"firstnames":["Zanele"],"suffixes":[]},{"propositions":[],"lastnames":["Ayres"],"firstnames":["Frances"],"suffixes":[]},{"propositions":[],"lastnames":["Mhlanga"],"firstnames":["Donald"],"suffixes":[]},{"propositions":[],"lastnames":["Oosthuysen"],"firstnames":["Brent"],"suffixes":[]},{"propositions":[],"lastnames":["Lambson"],"firstnames":["Bronwen","E"],"suffixes":[]},{"propositions":[],"lastnames":["Kgagudi"],"firstnames":["Prudence"],"suffixes":[]},{"propositions":[],"lastnames":["Tegally"],"firstnames":["Houriiyah"],"suffixes":[]},{"propositions":[],"lastnames":["Iranzadeh"],"firstnames":["Arash"],"suffixes":[]},{"propositions":[],"lastnames":["Doolabh"],"firstnames":["Deelan"],"suffixes":[]},{"propositions":[],"lastnames":["Tyers"],"firstnames":["Lynn"],"suffixes":[]},{"propositions":[],"lastnames":["Chinhoyi"],"firstnames":["Lionel","R"],"suffixes":[]},{"propositions":[],"lastnames":["Mennen"],"firstnames":["Mathilda"],"suffixes":[]},{"propositions":[],"lastnames":["Skelm"],"firstnames":["Sango"],"suffixes":[]},{"propositions":[],"lastnames":["Wibmer"],"firstnames":["Constantinos","Kurt"],"suffixes":[]},{"propositions":[],"lastnames":["Bhiman"],"firstnames":["Jinal","N"],"suffixes":[]},{"propositions":[],"lastnames":["Ueckermann"],"firstnames":["Veronica"],"suffixes":[]},{"propositions":[],"lastnames":["Rossouw"],"firstnames":["Theresa"],"suffixes":[]},{"propositions":[],"lastnames":["Boswell"],"firstnames":["Michael"],"suffixes":[]},{"propositions":["de"],"lastnames":["Oliveira"],"firstnames":["Tulio"],"suffixes":[]},{"propositions":[],"lastnames":["Williamson"],"firstnames":["Carolyn"],"suffixes":[]},{"propositions":[],"lastnames":["Burgers"],"firstnames":["Wendy","A"],"suffixes":[]},{"propositions":[],"lastnames":["Ntusi"],"firstnames":["Ntobeko"],"suffixes":[]},{"propositions":[],"lastnames":["Morris"],"firstnames":["Lynn"],"suffixes":[]},{"propositions":[],"lastnames":["Moore"],"firstnames":["Penny","L"],"suffixes":[]}],"doi":"10.1101/2021.03.06.434193","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Moyo-Gwete et al. - 2021 - SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.pdf:pdf","journal":"bioRxiv","keywords":"OA,fund_ack,original","mendeley-tags":"OA,fund_ack,original","month":"mar","pages":"2021.03.06.434193","pmid":"33688657","publisher":"Cold Spring Harbor Laboratory","title":"SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.","url":"http://www.ncbi.nlm.nih.gov/pubmed/33688657 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941631","year":"2021","bibtex":"@article{Moyo-Gwete2021a,\r\nabstract = {Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90{\\%} of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.},\r\nauthor = {Moyo-Gwete, Thandeka and Madzivhandila, Mashudu and Makhado, Zanele and Ayres, Frances and Mhlanga, Donald and Oosthuysen, Brent and Lambson, Bronwen E and Kgagudi, Prudence and Tegally, Houriiyah and Iranzadeh, Arash and Doolabh, Deelan and Tyers, Lynn and Chinhoyi, Lionel R and Mennen, Mathilda and Skelm, Sango and Wibmer, Constantinos Kurt and Bhiman, Jinal N and Ueckermann, Veronica and Rossouw, Theresa and Boswell, Michael and de Oliveira, Tulio and Williamson, Carolyn and Burgers, Wendy A and Ntusi, Ntobeko and Morris, Lynn and Moore, Penny L},\r\ndoi = {10.1101/2021.03.06.434193},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Moyo-Gwete et al. - 2021 - SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.pdf:pdf},\r\njournal = {bioRxiv},\r\nkeywords = {OA,fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nmonth = {mar},\r\npages = {2021.03.06.434193},\r\npmid = {33688657},\r\npublisher = {Cold Spring Harbor Laboratory},\r\ntitle = {{SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.}},\r\nurl = {http://www.ncbi.nlm.nih.gov/pubmed/33688657 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941631},\r\nyear = {2021}\r\n}\r\n","author_short":["Moyo-Gwete, T.","Madzivhandila, M.","Makhado, Z.","Ayres, F.","Mhlanga, D.","Oosthuysen, B.","Lambson, B. E","Kgagudi, P.","Tegally, H.","Iranzadeh, A.","Doolabh, D.","Tyers, L.","Chinhoyi, L. R","Mennen, M.","Skelm, S.","Wibmer, C. K.","Bhiman, J. N","Ueckermann, V.","Rossouw, T.","Boswell, M.","de Oliveira, T.","Williamson, C.","Burgers, W. A","Ntusi, N.","Morris, L.","Moore, P. L"],"key":"Moyo-Gwete2021a","id":"Moyo-Gwete2021a","bibbaseid":"moyogwete-madzivhandila-makhado-ayres-mhlanga-oosthuysen-lambson-kgagudi-etal-sarscov2501yv2b1351elicitscrossreactiveneutralizingantibodies-2021","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/33688657 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941631"},"keyword":["OA","fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["oa","fund_ack","original"],"search_terms":["sars","cov","501y","351","elicits","cross","reactive","neutralizing","antibodies","moyo-gwete","madzivhandila","makhado","ayres","mhlanga","oosthuysen","lambson","kgagudi","tegally","iranzadeh","doolabh","tyers","chinhoyi","mennen","skelm","wibmer","bhiman","ueckermann","rossouw","boswell","de oliveira","williamson","burgers","ntusi","morris","moore"],"title":"SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.","year":2021}